Clinical Trials

9 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Phase 1 Recruiting

12 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Phase 2 Recruiting

20 enrolled

Ovarian Neoplasms

NCT05922930 2026-02-19

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

GastrointestinalGynecologic

51 enrolled

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT07410494 2026-02-18

SELECT-CAR-NK

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

85 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT05075993 2025-12-26

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

DermatologicGastrointestinalGynecologicSarcoma

352 enrolled

Uveal Melanoma, Carcinoma, Hepatocellular, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

4 enrolled 8 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

22 enrolled

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT03449108 2025-11-21

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2 Active not recruiting

30 enrolled

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

BreastCNSDermatologicGynecologicSarcomaThoracic

3 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Active not recruiting

47 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04611126 2025-08-12

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05225363 2025-07-01

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Phase 1 Recruiting

33 enrolled

Phase 1/2 Active not recruiting

Platinum-Resistant Ovarian Carcinoma

NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

15 enrolled 12 charts

DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03610490 2025-04-17

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Phase 2 Terminated

16 enrolled 11 charts

GastrointestinalGynecologic

Ovarian Neoplasms, Colorectal Neoplasms

NCT03267680 2025-04-13

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Phase 2 Terminated

10 enrolled 19 charts

Uterine Cervical Dysplasia

NCT05714306 2025-03-05

CHUV-OVACURE

Phase 1/2 Withdrawn

Phase EARLY_PHASE1 Not yet recruiting

Ovarian Neoplasms

NCT06825455 2025-02-13

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

18 enrolled

DermatologicGynecologicThoracic

Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT06630611 2025-01-28

PragmaTIL

Phase 2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma

NCT03318900 2024-11-07

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

5 enrolled 8 charts

Ovarian Neoplasms

NCT01883297 2024-09-05

"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

3 enrolled

Fallopian Tube Neoplasms, Recurrence

NCT01606241 2024-08-21

Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

24 enrolled

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02865135 2024-01-11

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

GastrointestinalGynecologicHead & Neck

11 enrolled 18 charts

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms

NCT00562640 2023-09-15

Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)

12 enrolled 13 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00538031 2023-04-21

Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

52 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

7 enrolled 10 charts

Ovarian Neoplasms

NCT02978495 2022-12-28

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

154 enrolled

BreastGynecologic

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

GastrointestinalGynecologic

67 enrolled 16 charts

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT02562365 2022-07-27

ACTS

Phase 2 Unknown

130 enrolled

Ovarian Neoplasms

NCT04520074 2022-07-27

Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

Phase 3 Recruiting

590 enrolled

Ovarian Neoplasms

NCT02639650 2022-06-03

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Phase 3 Unknown

214 enrolled

Gestational Trophoblastic Disease

NCT02853318 2021-10-06

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

40 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03192059 2021-09-08

PRIMMO

43 enrolled

Phase EARLY_PHASE1 Unknown

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

NCT03814447 2021-08-10

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

10 enrolled

Ovarian Neoplasms

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

DermatologicGastrointestinalGynecologicHead & Neck

18 enrolled

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT01312376 2020-04-24

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

Phase 1 Terminated

18 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00007813 2020-02-17

Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

21 enrolled

Familial ependymoma, Ovarian Germ Cell Cancer, Testicular Germ Cell Tumor, Astrocytoma, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Sarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma

NCT00478452 2019-10-23

DC-Ova

14 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00003214 2019-05-15

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Phase 3 Completed

300 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

20 enrolled

Phase EARLY_PHASE1 Unknown

Ovarian Neoplasms, Recurrence

NCT03799913 2019-04-10

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

20 enrolled

Ovarian Neoplasms, Recurrence

NCT00652691 2019-04-08

Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer

48 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02948101 2019-03-12

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00002600 2019-02-06

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

23 enrolled